InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,940.29
(
1.05%
)
Post# of 252428
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: poorgradstudent post# 86440

Tuesday, 11/17/2009 6:09:17 PM

Tuesday, November 17, 2009 6:09:17 PM

Post# of 252428

This trial design can address the biological feedback of LDL levels when you try to modulate HDL using the CETP inhibitor alone. This arm also allows the sponsor to determine if the CETP inhibitor alone brings LDL down into the target range for benefit…

But isn’t it odd for a phase-2b trial conducted by a Big Pharma in a large indication to not have a bona fide control arm?


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up